What is the VEGF Trap?

The VEGF Trap is a drug candidate being developed by Regeneron Pharmaceuticals. It is designed to inhibit vascular endothelial growth factor (VEGF), a key component in the formation of new blood vessels that feed tumors.

What were the preliminary results of the Phase 1 study?

The 8-K filing does not provide specific details on the preliminary results. It only states that preliminary results from an ongoing Phase 1 study were announced. Investors would need to refer to the press release (Exhibit 99.1) for any available data, though Phase 1 studies typically focus on safety and dosage rather than efficacy.

What is the significance of a Phase 1 study?

Phase 1 studies are the first stage of drug testing in humans. Their primary purpose is to assess the safety of the drug, determine a safe dosage range, and identify side effects. While not designed to prove efficacy, positive safety findings are crucial for advancing to later stages of clinical trials.

What does 'open-label, dose-escalation' mean for this study?

'Open-label' means that both the patients and the researchers know which treatment is being administered. 'Dose-escalation' means that the study starts with a low dose of the drug and gradually increases it in different groups of patients to find the maximum tolerated dose.

REGN 8-K: Regulation FD

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced preliminary results on May 16, 2005, from an ongoing Phase 1 study for its VEGF Trap. This study involves administering the VEGF Trap intravenously to patients with advanced cancers. The announcement, made via a press release filed as an exhibit to this 8-K, provides an update on the drug's progress. While specific results are not detailed in the 8-K filing itself, the disclosure indicates that the company is actively pursuing the development of its VEGF Trap, a potentially significant asset in its pipeline, for cancer treatment.

Key Highlights

1Regeneron announced preliminary results from a Phase 1 study of its VEGF Trap.
2The study is an open-label, dose-escalation trial.
3VEGF Trap was administered intravenously to patients with advanced cancers.
4The announcement was made via a press release dated May 16, 2005.
5This filing (8-K) was made on May 16, 2005.
6The press release is included as Exhibit 99.1 to the 8-K filing.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (May 17, 2005)

Summary

Key Highlights

Frequently Asked Questions